Pharmaceutical
Technology
Health

OncoMed Pharmaceuticals

$0.9017
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.0382 (-4.06%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell OMED and other stocks, options, ETFs, and crypto commission-free!

About

OncoMed Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company, which focuses on discovering and developing novel therapeutics for cancer's growth, resistance, recurrence and metastasis. The company was founded by Michael F. Read More Clarke and Max Wicha in August 2004 and is headquartered in Redwood City, CA.

Employees
22
Headquarters
Redwood City, California
Founded
2004
Market Cap
36.34M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
252.02K
High Today
$0.95
Low Today
$0.855
Open Price
$0.95
Volume
204.42K
52 Week High
$3.45
52 Week Low
$0.5467

Collections

Pharmaceutical
Technology
Health
Biotechnology
Medical
Biopharmaceutical
Therapy
Cancer Prevention

News

Seeking AlphaMar 15

OncoMed declares one-time contractual right dividend; shares up 7% premarket

The board of OncoMed Pharmaceuticals (NASDAQ:OMED) has declared a one-time special dividend to stockholders in the form of a contractual right to receive cash payments related to Celgene's (NASDAQ:CELG) option on etigilimab.

404
StreetInsiderMar 15

Form 425 OncoMed Pharmaceuticals Filed by: OncoMed Pharmaceuticals Inc

Item 1.01. Entry into a Material Definitive Agreement. Contingent Value Rights Agreement On March 14, 2019, OncoMed Pharmaceuticals, Inc. (“ OncoMed ” or the “ Company ”) entered into a Contingent Value Rights Agreement (the “ CVR Agreement ”) with Computershare Inc., as rights agent, pursuant to which OncoMed’s common stockholders of record as of the close of business on April 5, 2019 (the “ Record Date ”) will receive one contingent value right (each, a “CVR”) for each outstanding share of common stock,...

3
Yahoo FinanceMar 15

OncoMed Pharmaceuticals Declares Special Dividend of Contingent Value Rights

REDWOOD CITY, Calif., March 15, 2019 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals, Inc. (“OncoMed”) (OMED), a clinical-stage biopharmaceutical company focused on discovering and developing novel anti-cancer therapeutics, today announced that its board of directors declared a one-time special dividend in the form of a contractual right to receive, on a pro rata basis, cash payments from OncoMed upon the actual receipt by OncoMed or its affiliates of certain contingent cash amounts in the future following the ...

97

Earnings

-$0.41
-$0.19
$0.03
$0.25
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Estimated
-$0.22 per share
Actual
-$0.12 per share

Popular Stocks

All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.